HCPCS Code J7328: Hyaluronan or Derivative, Gel-Syn, for Intra-articular Injection, 0.1 mg

Report J7328 for Gel-Syn intra-articular injections in patients with knee osteoarthritis unresponsive to conservative therapy. Ensure correct dose reporting.

Use Code

## **What is HCPCS code J7328?** HCPCS code J7328 is the specific code used to report Gel-Syn, a hyaluronan derivative indicated for intra-articular injection into the knee joint. It is billed per 0.1 mg, so precise documentation of the dosage is necessary for correct reimbursement. Gel-Syn is a prescription viscosupplement that mimics the properties of hyaluronic acid found in natural synovial fluid, improving joint lubrication and reducing pain in patients with symptomatic knee osteoarthritis. This injection is appropriate when conservative pharmacologic therapy and nonpharmacologic treatments, such as weight loss, simple analgesics, physical therapy, or oral NSAIDs, do not result in adequate symptom control. J7328 may help delay or avoid total knee replacement and is particularly beneficial for patients experiencing unilateral secondary osteoarthritis, post-traumatic osteoarthritis, or functionally limiting knee pain. Among the following HCPCS codes used in orthopedic and pain management care, J7328 plays a key role in tracking per-dose viscosupplementation for targeted relief.

## **Purpose of hyaluronan or derivative, Gel-Syn** Gel-Syn injections are part of a targeted treatment strategy for patients who have not responded adequately to conservative nonpharmacologic therapy, such as weight management, bracing, and structured exercise programs. The purpose is to provide a single intra-articular injection that can relieve joint discomfort, improve function, and lower pain scores. By mimicking hyaluronic acid found in synovial fluid, Gel-Syn enhances joint cushioning and may help restore more natural movement. This option is particularly valuable for patients with symptomatic knee osteoarthritis who are not yet candidates for surgery but require better symptom control to engage in physical therapy or improve daily function.

## **Documentation requirements for J7328** Accurate documentation is critical to justify the medical necessity of J7328. ### **Establishing diagnosis and necessity** You must provide a formal diagnosis of symptomatic osteoarthritis of the knee, supported by clinical findings such as persistent knee pain, reduced range of motion, or diagnostic imaging. Documentation must show that the patient failed to respond adequately to conservative pharmacologic and nonpharmacologic therapies. ### **Prior treatment history** Include detailed records of prior interventions, such as the use and duration of NSAIDs, simple analgesics, exercise regimens, bracing, assistive devices, or previous injections. Highlight why hyaluronic acid injection was determined to be the appropriate next step. ### **Dose and administration details** Specify the total dose in mg, the number of 0.1 mg units billed, the joint injected, and the injection site. If imaging guidance was used, indicate the technique. Follow-up instructions or the patient’s initial response should also be documented, especially when planning for subsequent courses.

## **Billing guidelines for J7328** ### **Per-dose billing structure** J7328 is billed based on dose codes of 0.1 mg per unit. For example, a single injection of 16 mg equates to 160 billable units. Use the correct drug code and verify alignment with payer rules to ensure reimbursement. ### **Avoid incorrect CPT pairings** Select the appropriate CPT code for the procedure and include imaging guidance codes when applicable. Modifier use may be required when injections are bilateral or staged. Confirm these CPT code requirements based on the payer’s billing and coding policies. ### **Track frequency limits** Many insurers allow only one injection per knee every six months. Repeat injections or subsequent courses of treatment require updated documentation, including pain score tracking and records demonstrating ongoing symptoms despite prior treatment.

## **Other related HCPCS codes** - **J7321** – Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg - **J7323** – Hyaluronan or derivative, Euflexxa, for intra-articular injection, 1 mg - **J7325** – Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg

Frequently asked questions

J7328 is the HCPCS code used to report administration of Gel-Syn, a hyaluronan-based injection for treating osteoarthritis of the knee.

J7328 is billed per 0.1 mg. If a patient receives 16 mg, you would report 160 units. Accurate documentation and dose tracking are critical.

Yes. Documentation must show the patient did not respond adequately to conservative nonpharmacologic and pharmacologic therapies before billing for J7328.